Newsletter
2025 Year in Review
By Mark Land, M.S., RAC-US, AAHP This year was dominated by change—political change, retail change, and change at AAHP. The association’s newsletter and special e-blasts continue to brief the homeopathic community—and sometime the AAHP membership…
Read MoreKey Departments at FDA Undergo Recent Leadership Changes
By Pete Evich, Vice President, Van Scoyoc Associates On December 3, FDA Commissioner Commission Marty Makary named Dr. Tracy Beth Høeg as the acting director of Center for Drug Evaluation and Research…
Read MoreStrengthening AAHP Behind the Scenes: A Year of Transition and Partnership
As we wrap up 2025 and look forward to a bright new year, we would like to offer members a closer look at the important work that has taken place behind the scenes…
Read MoreAAHP Reader Favorites of 2025
As 2025 winds down, we’re taking a moment to revisit the articles that resonated most with our community this year. These five top reads captured attention, highlighted key conversations, and reflected the…
Read MoreCustomer Service Requirements in the Age of E-Commerce
By Mark Land, M.S., RAC-US, AAHP We all might harbor in mind quaint notions of what customer service is. This is usually based on our personal expectations when purchasing products…
Read MoreServicing Retail Customer Accounts with Promotional Content
By Alissa Gould, Boiron USA Director of Corporate Communications and Public Affairs Typically, we think of customer service as caring for our end users — the consumers of our medicines. But don’t…
Read MoreHandling Consumer Complaints
By Eric L. Foxman, Pharm. (Ret.), AAHP Secretary This article originally appeared in the August 2012 hardcopy-only edition of the AAHP Network News. The importance of managing consumer complaints is underscored by the importance FDA gives…
Read MoreInvestigating Consumer Complaints
By Mary Beth Watkins This article originally appeared in the September 2012 hardcopy-only edition of the AAHP Network News. Question: What should be included in the investigation and report of a consumer…
Read MoreFDA Issues Warning Letters Alleging Unapproved New Drug Status and CGMP Non-Compliance
By Alvin J. Lorman, AAHP Counsel The Food and Drug Administration (FDA) has issued two Warning Letters that should be of intertest to all manufacturers and distributors of homeopathic drugs. …
Read MoreQuality by Design
By Mark Land, M.S., RAC-US, AAHP Quality by Design (QbD) is a systematic approach to product and process development that begins with predefined objectives and emphasizes product and process understanding…
Read More